Aelis Farma SA (AELIS PA) stock market data APIs
€1.3372
-0.15(-11.2%)
as of September 15, 2025
Try our APIs with
free plan!
Aelis Farma SA Financial Data Overview
Price chart is built with
Anychart
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Prev. Close
1.3372
Open
1.1905
High
1.3956
Low
1.1603
52 wk Range
0.672-5.55
Market Cap
19 191 K
Shares Outstanding
13 618 K
Revenue
5 562 K
EPS
-0.28
Beta
0.458
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aelis Farma SA data using free add-ons & libraries
Get Aelis Farma SA Fundamental Data
Aelis Farma SA Fundamental data includes:
- Net Revenue: 5 562 K
- EBITDA: -7 653 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-29
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aelis Farma SA News
New
3 European Penny Stocks With Market Caps Under €200M
The European market recently faced mixed results, with the pan-European STOXX Europe 600 Index ending slightly lower amid global growth concerns and a stronger euro. For investors looking beyond estab...
Down Syndrome Market Research and Global Forecast Report 2025-2035 | Rising Prevalence, Precision Medicine Advances, R&D Investments, and Advocacy-Driven Awareness Bolster Advances
Company Logo Down syndrome, caused by an extra chromosome 21, impacts physical and intellectual development. Advances in non-invasive prenatal testing (NIPT) and genetic screening offer earlier diagn...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
